Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

NCT06227026 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Diffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL: Anti-CD19 CAR-T cells

Sponsor

University of Utah